SecBot SecBot
8-K ·Filed Aug 6, 2026

TARS

Tarsus Pharmaceuticals, Inc.
MIXED
Impact 6/10
Horizonweeks Processed3mo ago SEC0001819790-26-000062
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ◆ Mixed

The PIPE provides critical funding for the Alkeus acquisition and pipeline, reducing near-term financing risk. However, the ~9% dilution at $56/share (likely a discount to the prior close) creates modest overhang. Monitor the Alkeus merger closing timeline and the effectiveness of the resale registration statement, which will determine when PIPE investors can exit. The 90-day lock-up provides a floor for near-term price action.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$65.33
T+0 close · Aug 6, 2026 · via day close
Latest settled
+14.57%
T+60 · $74.85
Vs SPY
+16.24%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $65.33entry
  2. T+1 · 3mo ago −0.83%α −1.44% · $64.79
  3. T+5 · 3mo ago +5.43%α +4.22% · $68.88
  4. T+20 · 3mo ago +27.36%α +26.76% · $83.21
  5. T+60 · 18d ago +14.57%α +16.24% · $74.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tarsus Pharmaceuticals announced an oversubscribed $125.0 million PIPE financing concurrent with its pending acquisition of Alkeus Pharmaceuticals. The company is selling 2,098,519 shares at $56.00/share and 133,625 pre-funded warrants at $55.9999 each to a syndicate including existing Alkeus investors (TCGX, Bain Capital Life Sciences, Wellington Management) and new/existing Tarsus investors. Proceeds will fund clinical development and commercial activities. The PIPE provides near-term funding certainty for the Alkeus acquisition and pipeline, but the ~9% dilution at a price below the prior close is a modest negative for existing holders.

Key Financial Metrics

Offering Size
$125.0M
Dilution
9%

Key Facts

  • Gross proceeds of approximately $125.0 million from a PIPE financing.
  • Sale of 2,098,519 shares of common stock at $56.00 per share and 133,625 pre-funded warrants at $55.9999 each.
  • PIPE includes participation from existing Alkeus investors (TCGX, Bain Capital Life Sciences, Wellington Management) and new/existing Tarsus investors (ADAR1 Capital Management, Sirenia Capital Management, RTW Investments, Vestal Point Capital).
  • PIPE is concurrent with the pending acquisition of Alkeus Pharmaceuticals, Inc. via a Merger Agreement dated July 31, 2026.
  • Closing expected on August 7, 2026, subject to customary conditions.
  • 90-day lock-up for company and directors/officers; company also restricted from issuing additional equity for 90 days.
  • Registration Rights Agreement requires filing a resale registration statement by the earlier of (i) one day after Alkeus merger close + 40 days after receiving Alkeus financials, or (ii) termination of the Merger Agreement.
  • Pre-funded warrants have a $0.0001 exercise price and a 4.99% (or 9.99% at holder election) beneficial ownership limitation.

Financial Impact

$125.0M gross proceeds from PIPE; dilution of ~9% based on ~2.23M new shares vs ~24.5M pre-offering shares outstanding (estimated from $2.6B market cap / $106 stock price).

dilutioncashshare count

Risk Factors

  • Dilution of ~9% from the PIPE issuance.
  • Risk that the Alkeus merger does not close, which would trigger different registration deadlines and potentially alter the use of proceeds.
  • Potential for further dilution if pre-funded warrants are exercised (though minimal at $0.0001 exercise price).
  • Market may view the PIPE as a signal that the company needed to raise capital to fund the Alkeus deal, potentially pressuring the stock.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001819790-26-000062
Exhibit: exhibit102_rra.htm0001819790-26-000062
Exhibit: exhibit41_formpfw.htm0001819790-26-000062
Document: tars-20260805.htm0001819790-26-000062
Document: pipereleasefinal.htm0001819790-26-000062
Document: 0001819790-26-000062-index-headers.html0001819790-26-000062

Track record

21 reports on TARS

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
  2. Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
  3. Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
  4. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  5. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
  6. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
  7. Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  8. Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
  10. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026